Clopidogrel therapy in patients undergoing coronary stenting: Value of a high-loading-dose regimen

Catheterization and Cardiovascular Interventions

Volumn 55, Issue 4, 2002, Pages 436-441

  Pache, Jürgen ^a,b   Kastrati, Adnan ^a   Mehilli, Julinda ^a   Gawaz, Meinrad ^a   Neumann, Franz Josef ^a   Seyfarth, Melchior ^a   Hall, Donald ^a   Braun, Siegmund ^a   Dirschinger, Josef ^a   Schömig, Albert ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Coronary disease; Platelets; Stents; Thrombosis

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DEATH; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK; THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VASCULAR DISEASE;

AGED; ANTIBODIES, MONOCLONAL; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PREOPERATIVE CARE; STENTS; TICLOPIDINE;

EID: 0036198762     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10092     Document Type: Article

References (29)

1. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents
2. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting
3. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study
4. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MAT-TIS)
5. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction
6. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention
7. Thrombotic thrombocytopenic purpura associated with ticlopidine: A review of 60 cases
8. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting: EPISTENT investigators
9. The antiplatelet effects of ticlopidine and clopidogrel
10. Intracoronary stenting and risk for major adverse cardiac events during the first month
11. Clopidogrel instead of ticlopidine after coronary stent placement: Is the switch justified?
12. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
13. Clopidogrel versus ticlopidine after intracoronary stent placement
14. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation
15. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting
16. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents
17. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS)
18. Ticlid or plavix post-stents (TOPPS): Randomization to 2 weeks of treatment
19. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement
20. Single-dose clopidogrel inhibition of platelet adenosine receptor function in patients with atherosclerotic coronary artery disease
21. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
22. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: Implications for patient selection
23. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade
24. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy
25. Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine
26. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
27. Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-Day and 6-month results in patients with smaller stents
28. Short term mortality lower with clopidogrel than ticlopidine following coronary artery stenting
29. A comparison of clopidogrel to ticlopidine therapy for the prevention of major adverse cardiac events at thirty days and six months following coronary stent implantation